A novel C. elegans p21-activated kinase (PAK) gene and associated loss-of-function phenotypes that facilitate screening for small molecule modulators of PAK activity in the nematode, Caenorhabditis elegans

Details for Australian Patent Application No. 2005200621 (hide)

International Classifications

Event Publications

3 March 2005 Complete Application Filed

Priority application(s): 04 001748.5 28.01.04 EP

9 June 2005 Section 223 Application Allowed

Aventis Pharma Deutschland GmbH The time in which to claim the convention priority date has been extended to 28 Feb 2005. Address for service in Australia - Watermark Patent & Trademark Attorneys 290 Burwood Road Hawthorn VIC 3122

11 August 2005 Application Open to Public Inspection

Published as AU-B-2005200621

22 December 2005 Assignment before Grant

Aventis Pharma Deutschland GmbH The application has been assigned to Sanofi-Aventis Deutschland GmbH

19 November 2009 Amendment Made

The nature of the amendment is: Add the name of the co-inventor Klebl, Bert

12 August 2010 Application Accepted

Published as AU-B-2005200621

9 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.